Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 22,335 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 22,335 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $984,303.45. Following the completion of the sale, the chief executive officer owned 2,230,721 shares in the company, valued at $98,307,874.47. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

Shares of TEM stock opened at $46.49 on Friday. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The firm has a market capitalization of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99. The business has a 50 day simple moving average of $49.02 and a 200 day simple moving average of $59.39. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same period in the prior year, the company posted ($0.24) EPS. The business’s revenue for the quarter was up 36.1% compared to the same quarter last year. On average, equities research analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on TEM shares. TD Cowen boosted their price target on shares of Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Mizuho assumed coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price for the company. Robert W. Baird assumed coverage on Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group started coverage on shares of Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.64.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. Royal Bank of Canada lifted its position in shares of Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after buying an additional 17,359 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Tempus AI during the first quarter worth approximately $116,000. Prudential Financial Inc. acquired a new position in shares of Tempus AI in the 2nd quarter valued at $276,000. Russell Investments Group Ltd. raised its stake in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after buying an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock valued at $13,446,000 after buying an additional 204,629 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.